Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
841 to 860 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A Large Case-Control Study Performed in Spanish Population Suggests That RECQL5 Is the Only RECQ Helicase Involved in Breast Cancer Susceptibility. | Cancers (Basel) | 2022 | 36230663 | PubTator, text mining | PubMed |
| Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome. | Cancers (Basel) | 2022 | 36230639 | PubTator, text mining | PubMed |
| Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. | Cancers (Basel) | 2022 | 36230543 | PubTator, text mining | PubMed |
| Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy. | Life Sci Alliance | 2022 | 36229065 | PubTator, text mining | PubMed |
| Landscape of germline cancer predisposition mutations testing and management in pediatrics: Implications for research and clinical care. | Front Pediatr | 2022 | 36225340 | PubTator, text mining | PubMed |
| Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland. | Prostate Int | 2022 | 36225282 | PubTator, text mining | PubMed |
| Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer. | Oncogene | 2022 | 36224341 | PubTator, text mining | PubMed |
| Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors. | Onco Targets Ther | 2022 | 36217436 | PubTator, text mining | PubMed |
| Loss of ribonuclease DIS3 hampers genome integrity in myeloma by disrupting DNA:RNA hybrid metabolism. | EMBO J | 2022 | 36215697 | PubTator, text mining | PubMed |
| Pan-cancer analysis of LncRNA XIST and its potential mechanisms in human cancers. | Heliyon | 2022 | 36212008 | PubTator, text mining | PubMed |
| Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci. | J Natl Cancer Inst | 2022 | 36210504 | PubTator, text mining | PubMed |
| The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer. | Mol Oncol | 2022 | 36209367 | PubTator, text mining | PubMed |
| Segregation analysis of 17,425 population-based breast cancer families: Evidence for genetic susceptibility and risk prediction. | Am J Hum Genet | 2022 | 36206742 | PubTator, text mining | PubMed |
| Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. | Cancer Res | 2022 | 36206301 | PubTator, text mining | PubMed |
| Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India. | Ecancermedicalscience | 2022 | 36200007 | PubTator, text mining | PubMed |
Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations. | Ther Adv Med Oncol | 2022 | 36199621 | PubTator, text mining | PubMed |
| Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report. | JTO Clin Res Rep | 2022 | 36188633 | PubTator, text mining | PubMed |
| BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma. | Cancer Res Commun | 2022 | 36187937 | PubTator, text mining | PubMed |
| Molecular factors, diagnosis and management of gastrointestinal tract neuroendocrine tumors: An update. | World J Clin Cases | 2022 | 36186187 | PubTator, text mining | PubMed |
| Phosphoproteomics reveals that cinobufotalin promotes intrahepatic cholangiocarcinoma cell apoptosis by activating the ATM/CHK2/p53 signaling pathway. | Front Oncol | 2022 | 36185307 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=43